Depression matters because it reaches far beyond mood. It is the single largest contributor to disability worldwide, accounting for over 36% of all disability-adjusted life years globally, and it affects roughly 332 million people. Its consequences ripple through the body, the brain, the workplace, and the economy, making it one of the most significant health challenges of our time.
The Scale of the Problem
About 4% of the entire global population lives with depression at any given time, including 5.7% of adults. Women are affected about 1.5 times more often than men, with rates of 6.9% for women compared to 4.6% for men. More than 10% of pregnant women and new mothers experience depression. Among older adults over 70, the rate reaches 5.9%.
These numbers translate into enormous human cost. In 2021, approximately 727,000 people died by suicide, and suicide is the third leading cause of death among people aged 15 to 29. The lifetime risk of suicide among people with untreated depression is nearly 20%, a figure that underscores why early identification and treatment are not optional but essential.
Depression Changes the Brain
Depression is not simply feeling sad. It produces measurable physical changes in the brain. MRI studies consistently show that people with major depression have reduced volume in the hippocampus, the brain region central to memory, learning, and emotional regulation. In one study comparing 39 people with depression to 34 healthy controls, the right hippocampus was noticeably smaller in the depression group, with reductions concentrated in both the front and back portions of the structure.
Some of these changes appear to be built into the condition itself rather than caused by medication or other factors. Researchers describe them as “trait changes,” meaning they may be present from the onset of the illness. A history of physical abuse correlates with even greater volume loss, suggesting that trauma compounds the brain’s vulnerability. These structural differences help explain why depression affects concentration, decision-making, and the ability to form new memories.
Heart Disease and Physical Health
Depression significantly raises the risk of cardiovascular disease, and the relationship follows a dose-response pattern: the more severe the depression, the higher the risk. CDC data from over a decade of national health surveys shows that among women aged 20 to 39, 41.9% of those without depression had high lifetime cardiovascular risk. That figure jumped to 53.2% for women with mild depression and 66.5% for women with major depression.
Men show the same trend. Among men aged 20 to 39, high lifetime cardiovascular risk rose from 53.3% without depression to 64.8% with mild symptoms and 74.4% with major depression. For both sexes, each step up in depression severity added roughly 10 percentage points of cardiovascular risk. This connection makes depression not just a mental health issue but a predictor of heart attacks, strokes, and early death from cardiovascular causes.
The Economic Toll
Mental disorders collectively cost the global economy an estimated $5 trillion per year when measured by the total years of healthy life they take away. Depression drives the largest share of that burden. These costs come from two directions: direct spending on medical care, hospitalizations, and outpatient visits, and indirect costs from lost income and reduced productivity. Projections suggest these losses will continue growing, potentially reaching $3 trillion annually by 2030 even by more conservative estimates that focus on productivity alone.
At the individual workplace level, the numbers are striking. Employees with depression report missing an average of 8% of their scheduled working hours in a given week due to their condition. But absenteeism is only part of the picture. The larger cost comes from presenteeism, showing up to work but functioning at reduced capacity. Workers with depression rate their on-the-job impairment at about 35% of total hours worked, meaning roughly 12 hours per week of diminished productivity. Combined, depression-related absenteeism and impaired work performance account for more than 14 hours of lost productivity per employee per week.
Lasting Effects on Young People
When depression strikes during childhood or adolescence, it doesn’t just affect the present. A meta-analysis pooling data from 22 studies found a consistent link between early depression and lower educational attainment later in life. Adolescents with depression are less likely to complete high school and less likely to pursue postgraduate education. The association is modest in statistical terms but carries outsized real-world consequences, because lower educational attainment predicts unemployment, housing instability, poor physical health, and future suicide attempts.
Interestingly, one study found that depression at age 12 was linked to slightly better performance on advanced exams at age 18 after adjusting for other factors, hinting that the relationship between depression and academic ability is more nuanced than simple decline. Still, the overall pattern is clear: depression during formative years narrows opportunities in adulthood, creating a cycle that is difficult to break without intervention.
Treatment Works, but Gaps Remain
One of the most important reasons depression deserves attention is that it responds to treatment. First-line antidepressant therapy produces a meaningful response in 40 to 60% of patients, and full remission occurs in 30 to 45% of cases. Therapy-based approaches show comparable effectiveness for many people. These numbers mean that for a significant majority, the condition can be substantially improved or resolved.
The gap between what treatment can do and what actually happens is enormous. Most people with depression worldwide receive no treatment at all, whether due to lack of access, stigma, cost, or failure to recognize the condition. Given that untreated depression carries a nearly 20% lifetime suicide risk, shrinks brain structures involved in memory and decision-making, raises cardiovascular risk by double digits, and costs the global economy trillions of dollars, closing that treatment gap is one of the highest-value interventions in all of public health.